COMP <GO>
ELAN vs LLY // 10Y YIELD & FRED MACRO BETA
Elanco Animal Health Incorporated (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ELAN 3
— LLY 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ELAN
LAST: $23.06 (-0.77%) • MKT CAP: $11.61B
macro-sensitivity
0.96
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | 83.64% | -28.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 32.36% | -34.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 2.30% | +0.15 | ELAN | /fcf-yield <GO> |
| Operating Margin | -6.00% | 40.21% | -46.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 31.90% | -36.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 45.51% | -39.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.24 | 9.29 | -8.05 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 77.9 | -25.42 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.96 | 0.51 | +0.45 | ELAN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 26.3x | -6.25 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.61B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | LLY REV | ELAN GROSS % | LLY GROSS % | ELAN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | $65.18B | 55.0% | 83.0% | $284.0M | $16.81B |
| FY 2024 | $4.44B | $45.04B | 54.9% | 81.3% | $394.0M | $8.82B |
| FY 2023 | $4.42B | $34.12B | 44.0% | 79.3% | $72.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
LLY // BETA 0.51